Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Endometrial Cancer | Research

The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases

Authors: Xuewu You, Yangyang Dong, Jiaqi Wang, Yuan Cheng, Yuanyuan Jia, Xiaobo Zhang, Jianliu Wang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Pure uterine serous carcinoma (p-USC) and mixed tumors with serous component (m-USC) are aggressive subtypes of endometrial cancer associated with high mortality rates. This retrospective study aimed to compare clinicopathologic features and outcomes of p-USC and m-USC in a single center.

Methods

This study retrospectively reviewed patients diagnosed with USC at Peking University People’s Hospital between 2008 and 2022. T-tests and chi-square tests were used to compare clinicopathological characteristics between p-USC and m-USC. Kaplan-Meier survival curve and Cox regression analysis were used to analyze the impact of clinical and pathological variables on OS and PFS.

Results

Among the 91 patients who underwent surgery, 65.9% (n = 60) were p-USC, and 34.1% (n = 31) were m-USC. Patients with p-USC had earlier menopause (P = 0.0217), a lower rate of progesterone receptor(PR) expression (P < 0.001), and were more likely to have positive peritoneal cytology (P = 0.0464). After a median follow-up time of 40 months, 28 (46.7%) p-USC and 9 (29%) m-USC patients had progression disease, 18 (30%) and 8 (25.8%) patients died of their disease. 5-year PFSR were 51.2% and 75.3%, respectively, and 5-year OS rates were 66% and 67.4%. Kaplan-Meier survival analysis showed that p-USC was more likely to relapse than m-USC (P = 0.034), but there was no significant difference in OS. Cox regression analysis showed that lymph node metastasis and surgical approach were risk factors for OS, and myoinvasion depth ≥ 1/2 was an independent risk factor for PFS.

Conclusions

p-USC was more likely to relapse than m-USC, but there was no significant difference in OS between the two subtypes.
Literature
1.
go back to reference McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and Grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database Analysis. Int J Gynecol Cancer. 2017;27(1):85–92.CrossRefPubMed McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and Grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database Analysis. Int J Gynecol Cancer. 2017;27(1):85–92.CrossRefPubMed
2.
go back to reference Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–53. Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–53.
3.
4.
go back to reference Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96(3):579–82.CrossRefPubMed Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96(3):579–82.CrossRefPubMed
5.
go back to reference Black C, Feng A, Bittinger S, Quinn M, Neesham D, McNally O. Uterine papillary serous carcinoma: a single-Institution Review of 62 cases. Int J Gynecol Cancer. 2016;26(1):133–40.CrossRefPubMed Black C, Feng A, Bittinger S, Quinn M, Neesham D, McNally O. Uterine papillary serous carcinoma: a single-Institution Review of 62 cases. Int J Gynecol Cancer. 2016;26(1):133–40.CrossRefPubMed
6.
go back to reference Zhong X, Wang J, Kaku T, Wang Z, Li X, Wei L. Prognostic factors of Uterine Serous Carcinoma-A Multicenter Study. Int J Gynecol Cancer. 2018;28(6):1138–44.CrossRefPubMed Zhong X, Wang J, Kaku T, Wang Z, Li X, Wei L. Prognostic factors of Uterine Serous Carcinoma-A Multicenter Study. Int J Gynecol Cancer. 2018;28(6):1138–44.CrossRefPubMed
7.
go back to reference Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–9.CrossRefPubMed Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–9.CrossRefPubMed
8.
go back to reference Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.CrossRefPubMed Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.CrossRefPubMed
9.
go back to reference Roelofsen T, van Ham MA, van Wiersma JM, Zomer SF, Bol M, Massuger LF, Bulten J. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol. 2012;120(6):1371–81.CrossRefPubMed Roelofsen T, van Ham MA, van Wiersma JM, Zomer SF, Bol M, Massuger LF, Bulten J. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol. 2012;120(6):1371–81.CrossRefPubMed
10.
go back to reference Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295–308.CrossRefPubMed Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295–308.CrossRefPubMed
11.
go back to reference Tymon-Rosario JR, Gorman M, Santin AD. Targeted therapies in the treatment of Uterine Serous Carcinoma. Curr Treat Options Oncol. 2022;23(12):1804–17.CrossRefPubMed Tymon-Rosario JR, Gorman M, Santin AD. Targeted therapies in the treatment of Uterine Serous Carcinoma. Curr Treat Options Oncol. 2022;23(12):1804–17.CrossRefPubMed
12.
go back to reference Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, Fyles A, Mitchell M, Narod SA. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477–81.CrossRefPubMed Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, Fyles A, Mitchell M, Narod SA. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477–81.CrossRefPubMed
13.
go back to reference Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 2000;96(1):28–32.PubMed Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 2000;96(1):28–32.PubMed
14.
go back to reference Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC Jr., Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11.CrossRefPubMed Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC Jr., Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11.CrossRefPubMed
15.
go back to reference Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16(6):600–10.CrossRefPubMed Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16(6):600–10.CrossRefPubMed
16.
go back to reference Shimizu M, Yamanaka K, Azumi M, Tomimoto M, Washio K, Takahashi R, Nagamata S, Murata Y, Yamasaki Y, Terai Y. A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma. J Ovarian Res. 2021;14(1):87.CrossRefPubMedPubMedCentral Shimizu M, Yamanaka K, Azumi M, Tomimoto M, Washio K, Takahashi R, Nagamata S, Murata Y, Yamasaki Y, Terai Y. A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma. J Ovarian Res. 2021;14(1):87.CrossRefPubMedPubMedCentral
17.
go back to reference Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, Chiang S, Murali R, Rios-Doria EV, Alektiar KM, Aghajanian C, Abu-Rustum NR, Ladanyi M, et al. Clinicopathologic and genomic analysis of TP53-Mutated endometrial carcinomas. Clin Cancer Res. 2021;27(9):2613–23.CrossRefPubMedPubMedCentral Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, Chiang S, Murali R, Rios-Doria EV, Alektiar KM, Aghajanian C, Abu-Rustum NR, Ladanyi M, et al. Clinicopathologic and genomic analysis of TP53-Mutated endometrial carcinomas. Clin Cancer Res. 2021;27(9):2613–23.CrossRefPubMedPubMedCentral
18.
go back to reference Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous carcinomas that Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018;36(20):2044–51.CrossRefPubMed Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous carcinomas that Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018;36(20):2044–51.CrossRefPubMed
19.
go back to reference Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.CrossRefPubMed Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.CrossRefPubMed
20.
go back to reference Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, Mariani A. Management of endometrial cancer: issues and controversies. Eur J Gynaecol Oncol. 2016;37(1):6–12.PubMed Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, Mariani A. Management of endometrial cancer: issues and controversies. Eur J Gynaecol Oncol. 2016;37(1):6–12.PubMed
21.
go back to reference Milgrom SA, Kollmeier MA, Abu-Rustum NR, Makker V, Gardner GJ, Barakat RR, Alektiar KM. Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol. 2013;130(1):49–53.CrossRefPubMed Milgrom SA, Kollmeier MA, Abu-Rustum NR, Makker V, Gardner GJ, Barakat RR, Alektiar KM. Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol. 2013;130(1):49–53.CrossRefPubMed
22.
go back to reference Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, Roman LD, Wright JD, Harter P, Klar M. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Eur J Cancer. 2020;133:33–46.CrossRefPubMedPubMedCentral Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, Roman LD, Wright JD, Harter P, Klar M. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Eur J Cancer. 2020;133:33–46.CrossRefPubMedPubMedCentral
23.
go back to reference Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110(3):293–8.CrossRefPubMed Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110(3):293–8.CrossRefPubMed
24.
go back to reference Roelofsen T, Mingels M, Hendriks JC, Samlal RA, Snijders MP, Aalders AL, Bulten J, van Ham MA, Massuger LF. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. Int J Biol Markers. 2012;27(3):e263–271.CrossRefPubMed Roelofsen T, Mingels M, Hendriks JC, Samlal RA, Snijders MP, Aalders AL, Bulten J, van Ham MA, Massuger LF. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. Int J Biol Markers. 2012;27(3):e263–271.CrossRefPubMed
25.
go back to reference Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012;22(3):417–24.CrossRefPubMed Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012;22(3):417–24.CrossRefPubMed
26.
go back to reference Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021;160(1):322–32.CrossRefPubMed Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021;160(1):322–32.CrossRefPubMed
27.
go back to reference Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, et al. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecol Oncol. 2015;137(2):239–44.CrossRefPubMed Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, et al. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecol Oncol. 2015;137(2):239–44.CrossRefPubMed
28.
go back to reference Vogel TJ, Knickerbocker A, Shah CA, Schiff MA, Isacson C, Garcia RL, Goff BA. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. J Gynecol Oncol. 2015;26(1):25–31.CrossRefPubMedPubMedCentral Vogel TJ, Knickerbocker A, Shah CA, Schiff MA, Isacson C, Garcia RL, Goff BA. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. J Gynecol Oncol. 2015;26(1):25–31.CrossRefPubMedPubMedCentral
29.
go back to reference Fader AN, Drake RD, O’Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115(10):2119–27.CrossRefPubMed Fader AN, Drake RD, O’Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115(10):2119–27.CrossRefPubMed
30.
go back to reference Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115(2):244–8.CrossRefPubMed Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115(2):244–8.CrossRefPubMed
31.
go back to reference Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21–9.CrossRefPubMed Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21–9.CrossRefPubMed
32.
go back to reference Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, et al. NCCN Guidelines(R) insights: Uterine neoplasms, Version 3.2021. J Natl Compr Canc Netw. 2021;19(8):888–95.CrossRefPubMed Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, et al. NCCN Guidelines(R) insights: Uterine neoplasms, Version 3.2021. J Natl Compr Canc Netw. 2021;19(8):888–95.CrossRefPubMed
33.
go back to reference Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, et al. Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol. 2018;149(2):291–6.CrossRefPubMed Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, et al. Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol. 2018;149(2):291–6.CrossRefPubMed
34.
go back to reference Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, Ananth CV, Neugut AI, Hershman DL, Wright JD. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol. 2017;145(2):269–76.CrossRefPubMed Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, Ananth CV, Neugut AI, Hershman DL, Wright JD. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol. 2017;145(2):269–76.CrossRefPubMed
35.
go back to reference Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011;123(3):542–7.CrossRefPubMed Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011;123(3):542–7.CrossRefPubMed
Metadata
Title
The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases
Authors
Xuewu You
Yangyang Dong
Jiaqi Wang
Yuan Cheng
Yuanyuan Jia
Xiaobo Zhang
Jianliu Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11793-3

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine